Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis.

Childs LM, Paschalis EP, Xing L, Dougall WC, Anderson D, Boskey AL, Puzas JE, Rosier RN, O'Keefe RJ, Boyce BF, Schwarz EM.

J Bone Miner Res. 2002 Feb;17(2):192-9.

2.

Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis.

Goater JJ, O'Keefe RJ, Rosier RN, Puzas JE, Schwarz EM.

J Orthop Res. 2002 Mar;20(2):169-73.

3.

Inhibiting wear particles-induced osteolysis with doxycycline.

Zhang C, Tang TT, Ren WP, Zhang XL, Dai KR.

Acta Pharmacol Sin. 2007 Oct;28(10):1603-10.

4.

Suppression of polyethylene particle-induced osteolysis by exogenous osteoprotegerin.

von Knoch F, Heckelei A, Wedemeyer C, Saxler G, Hilken G, Brankamp J, Sterner T, Landgraeber S, Henschke F, Löer F, von Knoch M.

J Biomed Mater Res A. 2005 Nov 1;75(2):288-94.

PMID:
16088891
5.

Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity.

Yip KH, Zheng MH, Feng HT, Steer JH, Joyce DA, Xu J.

J Bone Miner Res. 2004 Nov;19(11):1905-16. Epub 2004 Sep 27.

6.

Protective effects of COX-2 inhibitor on titanium-particle-induced inflammatory osteolysis via the down-regulation of RANK/RANKL.

Geng D, Mao H, Wang J, Zhu X, Huang C, Chen L, Yang H, Xu Y.

Acta Biomater. 2011 Aug;7(8):3216-21. doi: 10.1016/j.actbio.2011.05.007. Epub 2011 May 11.

PMID:
21601661
7.

Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing.

Flick LM, Weaver JM, Ulrich-Vinther M, Abuzzahab F, Zhang X, Dougall WC, Anderson D, O'Keefe RJ, Schwarz EM.

J Orthop Res. 2003 Jul;21(4):676-84.

8.
9.
10.

Tumor necrosis factor-alpha/nuclear transcription factor-kappaB signaling in periprosthetic osteolysis.

Schwarz EM, Lu AP, Goater JJ, Benz EB, Kollias G, Rosier RN, Puzas JE, O'Keefe RJ.

J Orthop Res. 2000 May;18(3):472-80.

PMID:
10937636
11.
12.

The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.

Whang PG, Schwarz EM, Gamradt SC, Dougall WC, Lieberman JR.

J Orthop Res. 2005 Nov;23(6):1475-83. Epub 2005 Jul 6.

14.

RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.

Sordillo EM, Pearse RN.

Cancer. 2003 Feb 1;97(3 Suppl):802-12. Review.

15.
16.

NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.

Xing L, Bushnell TP, Carlson L, Tai Z, Tondravi M, Siebenlist U, Young F, Boyce BF.

J Bone Miner Res. 2002 Jul;17(7):1200-10.

17.

Quantitative small-animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis.

Schwarz EM, Benz EB, Lu AP, Goater JJ, Mollano AV, Rosier RN, Puzas JE, Okeefe RJ.

J Orthop Res. 2000 Nov;18(6):849-55.

PMID:
11192243
19.

Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities.

Wittrant Y, Theoleyre S, Couillaud S, Dunstan C, Heymann D, Rédini F.

Exp Cell Res. 2004 Feb 15;293(2):292-301.

PMID:
14729467
20.

Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.

Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP.

J Bone Miner Res. 2005 Sep;20(9):1659-68. Epub 2005 May 2.

Items per page

Supplemental Content

Write to the Help Desk